Abstract:What's New? Glucocorticoids are used to help reduce side effects associated with high‐dose chemotherapy. Recent evidence suggests, however, that glucocorticoids negatively impact the efficacy of chemotherapy and promote tumor progression. Here, in colorectal cancer (CRC) cells, investigation of mechanisms underlying the metastasis‐inducing effects of glucocorticoids shows that following glucocorticoid exposure, migration rates vary considerably in CRC cells with different glucocorticoid receptor (GR) expression levels. GRs were found to interact with ten‐eleven translocation enzymes (TETs), linking glucocorticoid signaling and epigenetic regulation. Co‐targeting of GR and TET with belinostat resulted in down‐regulation of metastasis‐associated genes, offering additional insight into relationships between glucocorticoids and cancer. Glucocorticoids (GCs), commonly used for anti‐inflammatory and cancer treatments, have been linked to the promotion of cancer metastasis. Yet, the molecular mechanisms behind this potential remain poorly understood. Clarifying these mechanisms is crucial for a nuanced understanding and potential refinement of GC therapies in the context of cancer treatment. In HEK293T cells, co‐immunoprecipitation (Co‐IP) and chromatin immunoprecipitation sequencing (ChIP‐seq) were used with antibodies of glucocorticoid receptor (GR) and ten‐eleven translocation enzymes (TET) family proteins (TET1, TET2, TET3). Drug repositioning was performed through the Connectivity Map database, using common target genes of GR and TET2 in HEK293 and HCT116 cell lines and differentially expressed genes (DEGs) of colorectal cancer (CRC). Cell migration and invasion were tested in CRC cell lines with varying GR expression, that is, HCT116 and HT29 cell lines. Dexamethasone (Dex) treatment resulted in a significant difference in cell migration rates in two CRC cell lines with disparate GR expression levels. Co‐IP and ChIP‐seq analyses substantiated the interaction between GR and TET family proteins in HEK293T cells. Belinostat, the selected compound, was successfully validated for its potential to counteract the effects of GC‐induced invasion in CRC cells in vitro. Transcriptomic analyses of Belinostat‐treated HCT116 cells revealed down‐regulation of target genes associated with cancer metastasis. This study provides valuable insights into the molecular mechanisms underlying GC‐induced metastasis, introducing newly repositioned compounds that could serve as potential adjuvant therapy to GC treatment. Furthermore, it opens avenues for exploring novel drug candidates for CRC treatment.

Activation of Glucocorticoid Receptor Inhibits the Stem-Like Properties of Bladder Cancer Via Inactivating the Β-Catenin Pathway.

Activation of cGAS-STING Signal to Inhibit the Proliferation of Bladder Cancer: The Immune Effect of Cisplatin

Inhibitory effect of glucocorticoid receptor on colorectal cancer growth by inhibiting glycolysis through autophagy

Glucocorticoid promotes metastasis of colorectal cancer via co‐regulation of glucocorticoid receptor and TET2

Glucocorticoid Receptor Β Acts As a Co-activator of T-Cell Factor 4 and Enhances Glioma Cell Proliferation.

Abstract LB-75: Glucocorticoid Receptor Activation Inhibits P53-Induced Apoptosis of MCF10A Myc Cells Via Induction of Protein Kinase C Epsilon

Dexamethasone inhibits pancreatic tumor growth in preclinical models: Involvement of activating glucocorticoid receptor

Glucocorticoid Receptor–irs-1 Axis Controls EMT and the Metastasis of Breast Cancers

Glucocorticoid Receptor Activation Inhibits P53-Induced Apoptosis of MCF10Amyc Cells Via Induction of Protein Kinase Cϵ

Lung Cancer Metastasis-Related Protein 1 Promotes the Transferring from Advanced Metastatic Prostate Cancer to Castration-Resistant Prostate Cancer by Activating the Glucocorticoid Receptor Α Signal Pathway.

Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance

EDARADD Silencing Suppresses the Proliferation and Migration of Bladder Cancer Cells

Dexamethasone inhibits androgen receptor-negative prostate cancer cell proliferation via the GR-FOXO3a-GAS5 axis

MicroRNA-708 activation by glucocorticoid receptor agonists regulate breast cancer tumorigenesis and metastasis via downregulation of NF-κB signaling

Ginsenoside rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma.

Dexamethasone activates c-Jun NH2-terminal kinase (JNK) which interacts with GR and protects it from ubiquitin-mediated degradation in NSCLC cells

Dexamethasone Suppresses DU145 Cell Proliferation and Cell Cycle Through Inhibition of the Extracellular Signal-Regulated Kinase 1/2 Pathway and Cyclin D1 Expression

Discovery of a Glucocorticoid Receptor (GR) Activity Signature Correlates with Immune Cell Infiltration in Adrenocortical Carcinoma.

Hypoxia- and Dexamethasone-Dependent HIF1α-glucocorticoid Receptor Interaction Leads to Degradation of Glucocorticoid Receptor in Pituitary Adenomas.

Glucocorticoid receptors orchestrate a convergence of host and cellular stress signals in triple negative breast cancer

Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1